VEGFA and glioblastoma: However, results of recent clinical trials revealed that Bevacizumab (Avastin®-Beva), a humanized anti-VEGF monoclonal antibody, and Cediranib, an orally available pan-VEGFR tyrosine kinase inhibitor, failed to show any effects on GBM patients’ overall survival [47–50].